GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial-mesenchymal transition

• Published in: Drug development and industrial pharmacy Vol. 46; no. 6; p. 916
• Main Authors: Yao, Xue-Min, Niu, Feng-Ju, Kong, Liang, Cai, Fu-Yi, Jing, Ming, Fu, Min, Liu, Jing-Jing, He, Si-Yu, Zhang, Lu, Liu, Xin-Ze, Ju, Rui-Jun, Li, Xue-Tao
• Format: Journal Article
• Language: English
• Published: England 02.06.2020
• Subjects: Breast Neoplasms - drug therapy; Cell Line, Tumor; Daunorubicin - chemistry; Diosgenin - analogs & derivatives; Diosgenin - chemistry; Epithelial-Mesenchymal Transition; Humans; Liposomes; epithelial–mesenchymal transition; dioscin; Breast cancer; targeted liposomes; daunorubicin
• ISSN: 1520-5762
• DOI: 10.1080/03639045.2020.1763397

Tumor invasion and metastasis are the nodus of anti-tumor. Epithelial cell-mesenchymal transition is widely regarded as one of the key steps in the invasion and metastasis of breast cancer. In this study, GGP modified daunorubicin plus dioscin liposomes are constructed and characterized. GGP modified daunorubicin plus dioscin liposome has suitable particle size, narrow PDI, zeta potential of about -5 mV, long cycle effect, and enhanced cell uptake due to surface modification of GGP making the liposome could enter the inside of the tumor to fully exert its anti-tumor effect. The results of experiments show that the liposome has superior killing effect on tumor cells and invasion. results indicate that the liposome prolongs the drug's prolonged time in the body and accumulates at the tumor site with little systemic toxicity. In short, the targeted liposome can effectively inhibit tumor invasion and may provide a new strategy for the treatment of invasive breast cancer.